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http://dx.doi.org/10.1016/j.jaad.2016.01.011Thrombophilic status may predict
prognosis in patients with metastatic
BRAFV600-mutated melanoma who are
receiving BRAF inhibitorsTo the Editor: Coagulation and cancer are strictly
linked. There is increasing evidence that theTable I. Logistic model: objective response according to th
BRAV600 melanoma receiving BRAF inhibitors
Variables OR
ETP HEPES ( for 500 increase) 1.547
Peak HEPES ( for 50 increase) 1.991
ETP 1 pmol/L TF ( for 500 increase) 0.891
Peak 1 pmol/L TF ( for 50 increase) 0.860
ETP 5 pmol/L TF ( for 500 increase) 0.821
Peak 5 pmol/L TF ( for 50 increase) 0.738
Platelets ( for 10 increase) 1.045
D-dimer ( for 10 increase) 0.946
PPL ( for 10 increase) 0.500
CI, Confidence interval; ETP, endogenous thrombin potential; OR, odds ractivation of the coagulation cascade correlates
with prognosis in preclinical models.1 Melanoma
cells are able to change the thrombophilic status (TS)
of endothelial cells and microenvironment,2,3
and contribute to angiogenesis and metastatic
progression through their proteolytic properties.4
We investigated the TS and hemostatic variables in
patients with BRAFV600-mutated melanoma (MPs)
with the hypothesis that circulating TS could
correlate with the extension of disease and predict
clinical response and outcome in metastatic MPs
who were receiving BRAF inhibitors (BRAFis). Two
cohorts of MPs consecutively observed from
November 2011 to August 2014 at the Division of
Oncology, Hospital Papa Giovanni XXIII, in
Bergamo, Italy were enrolled in the study. The
main cohort included 43 MPs who were prospec-
tively diagnosed with locally advanced or metastatic
melanoma and who were treated with BRAFis. The
second cohort included 37 MPs with stage I to III
melanoma. Forty healthy subjects (20 men and
20 women) were included as reference group for
coagulation biomarker studies. All investigations
were approved by the local ethical committee
(Comitato di Bioetica, Hospital Papa Giovanni
XXIII, Bergamo), and all study subjects gave
informed written consent to the study. The routine
hematologic assays, coagulation biomarker studies,
and immunohistochemical analyses used for
assessment of these melanoma tissues can be viewed
in Supplemental Table IS and Fig 1S (available online
at http://www.jaad.org).
Levels of D-dimer in the group of MPs were
significantly (P\ .01) higher compared to healthy
subjects. By using a logistic model, patients with
higher D-dimer levels at enrollment into the study
had a significantly lower probability to achieve an
objective response (Table I).
Using multivariate analysis and after adjusting
for age, sex, and tumor stage, high baseline levels ofe circulating thrombophilic status in patients with
95% CI P value
0.791-3.025 .2025
0.982-4.037 .0562
0.373-2.127 .7954
0.610-1.211 .3868
0.356-1.894 .6437
0.471-1.155 .1838
0.935-1.167 .4378
0.911-0.982 .0037
0.259-0.966 .0390
atio; PPL, endogenous plasma phospholipids; TF, tissue factor.
Fig 1. KaplaneMeier curves for D-dimer levels. A, Progression-free survival curves. Group 1:
D-dimer at baseline \161.5 and D-dimer \349 at subsequent visit. Group 2: D-dimer at
baseline\161.5 and D-dimer $349 at subsequent visit. Group 3: D-dimer at baseline $161.5.
B, Overall survival curves. Group 1: D-dimer at baseline \433.5 and D-dimer \149.5 at
subsequent visit. Group 2: D-dimer at baseline\433.5 and D-dimer$149.5 at subsequent visit.
Group 3: D-dimer at baseline $433.5.
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1256 LettersD-dimer were associated with a statistically
significantly poorer progression-free survival
(PFS) and overall survival (OS; hazard ratio [HR] for
10-ng/mL increase ¼ 1.01 [95% confidence interval
{CI}, 1.00-1.02]; P¼ .005 for PFS and HR for 10-ng/mL
increase ¼ 1.01 [95% CI, 1.01-1.02], P ¼ .001
for OS).
Based on the recursive partitioning algorithm,
the best predictive marker of PFS was a D-dimer
baseline level at the 161.5-ng/mL cutoff. Among
subjects with D-dimer levels \161.5 ng/mL, the
model split the subjects into groups depending
on D-dimer measured at a subsequent visit
(ie, 1 month after starting the BRAFi; cutoff:
349 ng/mL). According to this algorithm, a poorer
PFS was found in patients with low baseline
D-dimer levels and high D-dimer levels at a
subsequent visit (HR ¼ 9.23 [95% CI, 1.28-66.66];
P ¼ .0276) and in patients with high D-dimer
levels at baseline (HR ¼ 12.18 [95% CI, 2.8-53.09];
P ¼ .0009) when compared to patients with low
D-dimer levels both at baseline and at a
subsequent visit (Fig 1).
In addition, patients with high D-dimer levels at
baseline had a poorer OS (HR ¼ 13.40 [95% CI,
1.69-106.79]; P ¼ .0142) when compared to patients
with low D-dimer levels at baseline and at a
subsequent visit (1 month after starting the BRAFi;
Fig 1). Finally, tissue TS correlated with circulating
TS (Supplemental Table IS and Fig 1). Therefore,
among the investigated coagulation biomarkers,
only D-dimer showed a statistically significant
association with PFS and OS. Should our results be
validated in an independent cohort, D-dimer should
be incorporated as a stratification biomarker in
future clinical trials.
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http://dx.doi.org/10.1016/j.jaad.2015.11.006Distance of travel to phototherapy is
associated with early nonadherence: A
retrospective cohort studyTo the Editor: Phototherapy is an effective manage-
ment option for many dermatologic diseases.1,2
Although adherence to a phototherapy regimen is
essential for success, few studies have evaluated
factors impacting adherence among phototherapy
patients.3 Our retrospective cohort study aimed to
identify patient-related factors associated with early
non-adherence to phototherapy, in which patients
discontinue phototherapy for reasons unrelated to
treatment efficacy.
A database of phototherapy patients at Brigham
and Women’s Hospital (BWH) was generated
through a query of a registry of patients with medical
documentation at the BWH Phototherapy Center
from November 2009 to February 2015. The registry
contains information on the total number of photo-
therapy treatments, treatment indication, reasons for
declining treatment, distance to hospital, insurance,
and copay, all of which were included in the
analysis. All patients in the database had been
consented and counseled regarding phototherapy
at BWH during an office visit. This study was
approved by the Partners Institutional ReviewBoard.
Each patient record generated by the query was
individually reviewed. Patients who consented to
treatment after November 1, 2014 were excluded to
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The white blood cell differential count,
hematocrit, hemoglobin, red blood cell count,
and platelet count were determined by a CELL-
DYN Emerald hematology analyzer (Abbott
Diagnostics, Lake Forest, IL).
Peripheral venous blood was collected by a team
of experienced nurses from fasting patients in the
morning (9-11 AM). For patients in the main cohort,
blood samples were collected at the time of enroll-
ment and after 2 and 4 weeks of treatment with BRAF
inhibitors (BRAFis). For patients in the control
cohort, blood samples were collected only once, at
the time of enrollment.
After the application of a light tourniquet, venous
blood was collected using a 21-gauge needle into
6-mL tubes containing 3.2% citrate (0.109 mol/L, 1:9
vol/vol; BD Vacutainer, Becton, Dickinson and Co,
Franklin Lakes, NJ), after discarding the first 2 to 3mL
of blood. Anticoagulant was mixed during blood
collection with gentle inversion of the tube. The
tubes of blood were transported carefully to avoid
unnecessary agitation. Blood samples were kept at
room temperature (20-248C) and processed within
2 hours of collection. Platelet-poor plasma was
obtained by centrifugation at 2600 g for 15 minutes
at 248C, and platelet-free plasma (PFP) by further
centrifugation of platelet-poor plasma at 2600 g
for 15 minutes at 248C, avoiding application
of the centrifuge brake. Aliquots of PFP were
snap-frozen in liquid nitrogen and stored at 2808C
until use.
The duration of storage of plasma samples before
testing ranged from 4 to 6months. Aliquots of 1mL of
frozen samples of PFP were thawed for 10 minutes at
378C before use or until completely thawed. The
processing of blood samples and the assays for
coagulation study (ie, thrombin generation potential,
D-dimer and endogenous plasma phospholipids
[PPL] assay) were performed at the Laboratory of
the Hemostasis and Thrombosis Unit, Division of
Immunohematology and Transfusion Medicine,
Hospital Papa Giovanni XXIII, Bergamo.
Thrombin generation potential of plasma was
measured by the calibrated automated thrombogram
method (Thrombinoscope BV, Maastricht, The
Netherlands) using reagents from Diagnostica Stago
(Parsippany, NJ).E1 Briefly, 80 L of PFP were
incubated for 10 minutes at 378C with 20 L of
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
(HEPES) buffer (ie, in the absence of exogenous
tissue factor [TF]), 1 pmol/L TF, or 5 pmol/L TF.
Coagulation was started by the addition of CaCl2
and a fluorogenic thrombin substrate (Z-Gly-Gly-
Arg-AMC, Diagnostica Stago). Thrombin generationwas measured using a Fluoroskan Ascent reader
(Thermo Labsystems OY, Helsinki, Finland), and the
following parameters were calculated using software
(Thrombinoscope BV): peak height; the maximum
concentration of thrombin generated, expressed in
nmol/L of thrombin; and the endogenous thrombin
potential, expressed in nmol/L thrombin*min.
Thrombin generation assay was performed in batch
with inclusion of internal controls (2 levels) for
validation of the runs.
The STA-Procoag-PPL (Diagnostica Stago) assay
was used to evaluate the influence of PPL on the
activation of the coagulation cascade.E2 The PPL
assay measures clotting time, in the presence of
factor Xa and CaCl2, of a system in which all the
factors are present in physiologic levels (supplied by
procoagulant-PPL-depleted plasma), except the PPL,
which are supplied by the plasma sample being
tested. The assay was performed on an ACL TOP500
coagulometer (Instrumentation Laboratory,
Lexington, MA). Results are expressed as coagulation
time in seconds: the shorter the coagulation time, the
higher the PPL activity. PPL assay was performed in
batch with inclusion of positive and normal control
samples, provided by the kit, for validation of the
runs.
D-dimer levels were evaluated by the HemosIL D-
dimer HS, an automated latex enhanced immuno-
assay for the quantitative determination of D-dimer
levels, using ACL TOP500 coagulometer (both
manufactured by Instrumentation Laboratory).
Results were reported in ng/mL.
Metastatic and primary tumor samples were
retrieved from matrix metalloproteinase-19 and -14,
respectively. For the study, 4 m-thick sections were
cut from formalin-fixed, paraffin-embedded tissue
samples and immunostained according to standard
procedures. Briefly, antigen retrieval was performed
by immersing the slides in a thermostat bath contain-
ing Epitope Retrieval Solution EDTA (pH 9.0; Dako
Milan, Italy) for 20 minutes at 988C, followed by
cooling for 20 minutes at room temperature. After
blocking with UltraV Block (Thermo Scientific, Milan,
Italy), sections were incubated at 48C overnight with
anti-TF (FL-295; 1:50 Santa Cruz Biotechnology Inc,
Dallas, TX) and antithrombin receptor (ATAP2; pro-
tease-activated receptor-1, 1:25, Santa Cruz
Biotechnology Inc) antibodies. Signal was detected
by using UltraVision Quanto Detection System AP,
and the bound antibody was visualized using a
permanent Fast Red as chromogen (Thermo
Scientific). Nuclei were counterstained with Mayer
hematoxylin. A negative control was performed by
substituting the primary antibody with a nonim-
mune serum at the same concentration.
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a dermatopathologist (D. M.) and then indepen-
dently reviewed by a second pathologist (C. S.), both
blinded to clinical outcome. Discrepancies in inter-
pretation or scoring (\5% of cases) were resolved by
consensus conference at a double-headed micro-
scope. Staining intensity was scored as follows: 0 (no
staining), 11 (weak), 21 (moderate), or 31 (strong).
Samples were categorized as a continuous variable
and correlated with circulating TS using the
Spearman correlation coefficient. Cytoplasmic
cellular staining had to unequivocally exceed back-
ground to be considered positive.
Odd ratio was defined as the proportion of
patients with complete or partial response.
Progression-free survival (PFS) was defined as the
time from starting BRAFi treatment to the first
appearance of progressive disease or death from
any cause. Patients known to be alive and without
progressive disease at the time of analysis were
censored at their last available disease assessment.
PFS and OR were based on the European
Organization for Research and Treatment of
Cancer’s Response Evaluation Criteria in Solid
Tumors guidelines (v 1.1). Overall survival (OS)
was defined as the time from starting BRAFi to the
date of death from any cause or the date of the last
follow-up. The thrombophilic status of metastatic
BRAFV600-mutated melanoma and patients with
limited disease radically resected were compared
by means of Kruskal-Wallis test. Correlation
between TF and protease-activated receptor-1immunohistochemical overexpression and circu-
lating thrombophilic status was described using
Spearman correlation coefficient.
A logistic regression model was used to assess the
effect of the thrombophilic status on OR rate. Time-
to-event data were described by the Kaplan-Meier
curves. Cox proportional hazard models were used
for univariate and multivariate analysiseadjusted for
sex, age, and tumor stageeto estimate and test the
thrombophilic status for its association with OS and
PFS. Results were expressed for logistic models as
odds ratios and for Cox models as hazard ratios and
their relative 95% confidence intervals.
To identify a subset of patients with different
prognosis defined by the thrombophilic status at
baseline and 30 days after baseline, a recursive
partitioning analysis was used both for response
and survival. Once the classification tree was
defined, a Cox proportional hazard regression
model was used to estimate the hazard of
progression/death associated with risk groups
defined using cut-points suggested by the recursive
partitioning.
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Supplemental Fig 1S. Protease-activated receptor (PAR)-1 and tissue factor (TF) immuno-
histochemical expression in melanoma tissues. A, Weak PAR-1 staining in melanoma cells. B,
Q14 PAR-1 is strongly and diffusely expressed in melanoma cells. Note that endothelial cells
decorating blood vessels express PAR-1 protein. C, Example of PAR-1 staining in melanoma
Q15 tissues. Both cytoplasmic and membranous positivity is observed in tumor cells; scattered
stromal fibroblasts and macrophages are also positive.D,Weak and focal TF immunostaining in
scattered melanoma cells. E, Aggregates of melanoma cells with strong TF cytoplasmic
positivity. TF is also expressed in intratumoral flattened vascular endothelial cells. F, Strong TF
cytoplasmic immunostain (red ) in highly pigmented melanoma cells, partly colocalizes with
melanin pigment (brown). Note the presence of abundant extracellular granular melanin
depositions within the tumor. Scale bar ¼ 50 m. (A to F, Original magnification: 340.)
J AM ACAD DERMATOL
JUNE 2016
1256.e3 Letters
Supplemental Table IS. Correlation between immunohistochemical tissue factor/protease-activated
receptor-1 expression and circulating thrombophilic status at baseline
Correlation with IHC TF Correlation with IHC PAR-1
Spearman correlation
coefficient P value
Spearman correlation
coefficient P value
T0_ hepes_etp 0.11 .590 0.26 .185
T0_ hepes_peak 0.06 .761 0.02 .925
T0_TF1_etp 0.22 .261 0.48 .010
T0_TF1_peak -0.03 .867 0.06 .758
T0_TF5_etp 0.42 .025 0.47 .012
T0_TF5_peak 0.34 .074 0.22 .256
T0_plt_K_uL -0.03 .882 0.13 .507
D-dimer_T0 0.15 .445 0.39 .041
ppl_T0 0.03 .894 0.27 .157
etp, Endogenous thrombin potential; IHC, immunohistochemical; PAR, protease-activated receptor; ppl, endogenous plasma phospholipids;
plt, platelet; T0, time of enrollment; TF, tissue factor.
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